Liane Pinto

Director - Clinical Development Medical & RLT Prostate Cancer Novartis AG

Liane Pinto is a Clinical Development Medical Director with experience advancing cancer radioligand therapies. She provides medical leadership and strategic insight across clinical trial design, protocol development, and patient safety monitoring for studies spanning multiple phases. Liane works closely with cross-functional teams and global investigators to ensure the rigorous execution of impactful clinical trials. With deep expertise in clinical oncology research and development, she is committed to fostering innovation in precision cancer therapies. Her work is driven by a focus on improving patient outcomes and leveraging industry and medical experience to help shape the future of oncology care worldwide.

Seminars

Thursday 23rd July 2026
Virtual Presentation – Identifying Biomarkers to Overcome Patient Variability in 177-Lu-PSMA-617 Therapy to Guide Treatment Decisions & Optimize Outcomes in mCRPC
11:00 am
  • Identifying molecular, imaging, and circulating biomarkers that explain interpatient variability in response to ^177Lu-PSMA-617
  • Correlating biomarker profiles with treatment response, resistance, and toxicity to refine patient selection
  • Informing treatment sequencing and personalization strategies to optimize outcomes in mCRPC
Liane Pinto - Director - Clinical Development Medical & RLT Prostate Cancer, Novartis AG - Expert Speaker at the 5th Targeted Radiopharmaceuticals Summit US 2026, San Diego, CA